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Effects of the Proactive interdisciplinary
self-management (PRISMA) program on
self-reported and clinical outcomes in type
2 diabetes: a pragmatic randomized
controlled trial
Esther du Pon1,2* , Nanne Kleefstra3,4,5, Frits Cleveringa6, Ad van Dooren1, Eibert R. Heerdink1,7 and
Sandra van Dulmen8,9,10
Abstract
Background: Diabetes self-management education can be helpful for patients with type 2 diabetes in managing their
condition. We aimed to study the effects of the group-based PRoactive Interdisciplinary Self-MAnagement (PRISMA)
training program on self-reported and clinical outcomes in patients with type 2 diabetes treated in general practice.
Methods: Persons aged 18 years or older diagnosed with type 2 diabetes and treated in primary care were included. In
a randomized controlled trial design (1:1), patients were followed for 6 months with an extension phase of 6 months.
Block randomization was used. The patients with type 2 diabetes received either PRISMA in addition to usual care or
usual care only. All patients completed a range of validated questionnaires (including knowledge, skills, and confidence
for self-management [PAM], diabetes self-care behavior [SDSCA], health-related quality of life [EQ-5D], and emotional
well-being [WHO-5]). In addition, clinical outcomes (HbA1c, body mass index, systolic blood pressure, and cholesterol
levels) were collected during the routine diabetes checkups.
Results: Of the total sample (n = 193), 60.1% were men. The mean age was 69.9 years (SD = 9.1). No significant
differences were found on self-reported outcomes between the groups at 0, 6, and 12months. The clinical outcomes
were not reported due to a large number of missing values.
Conclusion: PRISMA did not improve self-reported outcomes in patients with type 2 diabetes treated in primary care.
It was not possible to make a statement about the clinical effects.
Trial registration: date: 16/07/2014, number: NL4550 (https://www.trialregister.nl/trial/4550).
Keywords: E-health, Type 2 diabetes, Primary care, Group education, Self-management
Background
In the Netherlands, 66 in 1000 persons were diagnosed with
type 2 diabetes mellitus in 2017 [1]. This rate is expected to
increase to 80 in 1000 persons by 2025 [2]. There will be no
comparable increase of health care providers, which compro-
mises the availability of face-to-face time between patients
and health care providers. In the Dutch health system, 95%
of patients with type 2 diabetes are treated in primary care by
a general practitioner (GP) and a practice nurse (PN) [3]. To
lower the risk of cardiovascular complications and manage
the increasing number of type 2 diabetes patients, encour-
aging self-management could be part of the solution. Self-
management can be defined as the active participation of
patients in their treatment [4] to minimize the impact of type
2 diabetes on their physical health and functioning and help
them to cope with the psychological effects of their illness
[5]. In the Netherlands, the quality of care for patients with
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type 2 diabetes has improved considerably in recent decades
[6]. In 1998, 55% of patients with type 2 diabetes younger
than 75 years had an HbA1c higher than 53mmol/mol. In
2013, this decreased to 29% [5]. For patients of 75 years
and older, similar trends were found for HbA1c. Poor
health behavior places patients with type 2 diabetes at an
increased risk of disease progression, impacting their qual-
ity of life and increasing their risk of additional health
problems and premature death [7–9].
The effectiveness of diabetes self-management ultimately
depends on patients’ adherence with lifestyle recommenda-
tions and treatment [10]. Patients need to understand the
principles and importance of self-management activities
[11], which makes diabetes self-management education a
key component of diabetes care. Diabetes self-management
education can be helpful for patients with type 2 diabetes in
managing their condition [12]. It aims not only to enhance
the patients’ medical understanding but also to improve
their intrinsic motivation, belief in their innate ability to
achieve goals (self-efficacy), illness perception, self-
management skills, and behavior [13]. Moreover, a recent
systematic review showed that diabetes self-management
education resulted in improved HbA1c [14]. Group-based
diabetes self-management education seems to be more ef-
fective than usual care and individual education at improv-
ing clinical, lifestyle, and psychosocial outcomes [15].
One example of an evidence-based diabetes self-
management education program is the group-based Proactive
Interdisciplinary Self-MAnagement (PRISMA) training pro-
gram. This program is based on the DESMOND (Diabetes
Education and Self-Management for Ongoing and Newly Di-
agnosed) program, which was developed and tested in the UK
[12, 16, 17]. DESMOND has proven to be (cost-)effective in
patients newly diagnosed with type 2 diabetes [16, 17].
PRISMA was adapted for use in type 2 diabetes in primary
care in the Netherlands and, in a previous study, seemed to
improve self-management behavior in terms of dietary behav-
iors, foot care, and action planning three months posttraining
[18]. However, the effects of PRISMA on self-reported and
clinical outcomes in a controlled setting are still unknown.
Therefore, the present study aimed to investigate the effects of
PRISMA on self-reported (knowledge, skills and confidence
for self-management, diabetes self-care behavior, health-related
quality of life, and emotional well-being) and clinical outcomes
in patients with type 2 diabetes treated in general practice.
Methods
Study design
The current study is part of the Diabetes Education and
Self-Management to Increase Empowerment (DESTINE)
study, described in detail elsewhere [19]. DESTINE has a
randomized controlled trial (RCT) design (1:1) in which
patients are followed for 6months with an extension
phase of another 6months. The study has a pragmatic
character, as it was carried out in daily practice. More de-
tails about the DESTINE study can be found in a previous
article [20]. Persons of 18 years and older diagnosed with
type 2 diabetes and treated in primary care were included.
Eight general practices in the eastern part of the
Netherlands participated, and eligible patients were in-
formed and asked to participate by GPs. Block
randomization was used to allocate participants to one of
the two groups. The participants were randomized in 10
blocks of 20 participants each. All criteria of the CON-
SORT checklist were reported (see Checklist S1) [21].
Description of the intervention
Patients with type 2 diabetes received either PRISMA in
addition to usual care or usual care only. According to the
guidelines of the Dutch College of GPs (NHG-Standaard),
usual care involves two to four visits per year with the PN
and at least one annual check-up with the GP. In addition,
all patients had access to an online care platform (e-Vita),
which aimed to support patients’ self-management skills.
The PRISMA program consisted of two group meetings
about type 2 diabetes, guided by different PNs and a diet-
ician specialized in diabetes care. These trainers strictly ad-
hered to the PRISMA protocol. In short, the following
topics were discussed: blood glucose levels, medication, nu-
trition, physical activity, complications, and personal risk fac-
tors. The PRISMA program has been described in detail
previously [20]. The PRISMA philosophy is to actively in-
volve patients and support them with the regulation of the
disease. PRISMA aims to support patients by making them
aware of their specific risk profile regarding the development
of complications and providing information about methods
to decrease their risks. Through a constructive approach, a
learning process is initiated that helps patients to (continue
to) work on promoting and monitoring their health. The
trainers encouraged the patients to discuss their individual
action plans with their health care provider during their next
consultation and bring up the topics important to them.
The two PRISMA meetings should therefore be seen as a
starting point to motivate/activate patients, with behavior
change as the final objective.
Outcomes
The outcomes of the study included self-reported data
(questionnaires), as well as clinical data retrieved from the
GP information systems.
Self-reported data
All patients completed a range of validated question-
naires at T0 (0 months, at the end of two PRISMA meet-
ings), T1 (6 months) and T2 (12 months). The following
questionnaires were used:
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1) The Patient Activation Measure (PAM). The PAM is a
validated 13-item instrument used to assess the know-
ledge, skills, and confidence for self-management [22].
Each item has four response categories with scores
from 1 (strongly disagree) to 4 (strongly agree). Higher
scores represent higher levels of patient activation.
2) The Summary of Diabetes Self-Care Activities
(SDSCA) scale. This scale assesses diabetes self-care
behavior over the previous 7 days in six domains:
diet, exercise, self-monitoring of blood glucose, foot
care, adherence and smoking [23]. The mean score
of each item was reported [24].
3) The EuroQol Five Dimension (EQ-5D-3 L) scale. This
questionnaire assesses health-related quality of life and
consists of two parts: the EQ-5D descriptive system and
the EQ visual analog scale (EQ-VAS) [25]. The EQ-5D-
3 L comprises five dimensions: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Each
dimension has three levels: no problems, some prob-
lems, and extreme problems. The EQ-5D-3 L includes a
visual analog scale (EQ-VAS) where individuals rate
their own health today on a scale from 0 (worst imagin-
able health) to 100 (best imaginable health).
4) The World Health Organization Well-being Index 5-
Item (WHO-5) scale. The WHO-5 assesses emotional
well-being and covers five items: subjective quality of life
based on positive mood (good spirits, relaxation), vitality
(being active and waking up fresh and rested), and gen-
eral interest (being interested in things) [26]. Each of
the five items is rated on a 6-point Likert scale from 0
(not present) to 5 (constantly present). Higher scores
represent higher levels of emotional well-being.
Additional demographics (gender, age, education level,
and type 2 diabetes duration) were included as patient
characteristics.
Clinical outcomes
The clinical outcomes described in the national primary
care guideline for diabetes treatment were included in
the study: HbA1c, body mass index (BMI), systolic blood
pressure, and cholesterol levels (total cholesterol, high-
density lipoprotein [HDL], and low-density lipoprotein
[LD]). These clinical outcomes were collected during the
routine diabetes checkups as part of usual care. These
data were individually linked to our own database and
anonymized. The data were collected at T0 (0 months),
T1 (6 months), and T2 (12 months). For T0, only data
available no more than 4months before the intervention
were used. For T1 and T2, only data 6 weeks before and
6 weeks after the measuring moment were used. Using a
research identification number for every patient, all data
were collected and analyzed anonymously.
Sample size calculation
A power calculation was carried out on the primary out-
come measure (usage of the e-Vita online care platform),
resulting in 81 participants needed per group [19]. The
usage of e-Vita was investigated by du Pon et al. (2019 –
submitted) in another study.
Statistical analysis
All analyses were conducted using IBM SPSS Statistics
version 22. Normally distributed data are presented as the
means and standard deviation, while skewed data are pre-
sented as the median and interquartile range. Dichotom-
ous/categorical data are presented as the numbers and
percentage of the total. To evaluate differences in target
variables between groups, a t-test was used if the data
were normally distributed; if not, a Mann-Whitney U test
was used. An intention to treat analysis was conducted.
Results
The inclusion period lasted 9months (June 2014 to February
2015). Of 1476 invited patients with type 2 diabetes treated
at participating general practices, 203 (13.8%) were included
in the study and signed the informed consent form: 101 pa-
tients were randomized in the intervention group; and 102,
in the control group. After inclusion, 10 patients (4.9%) with-
drew from the study: 6 in the intervention group and 4 in
the control group. Patients withdrew because of illness, im-
migration, or personal reasons. Therefore, 95 patients in the
intervention group and 98 patients in the control group were
analyzed. In the intervention group, 68 (71.6%) of 95 patients
attended at least one of the two PRISMA meetings in the
RCT phase. The patient flow chart is presented in Fig. 1 [21].
Patient characteristics
The patient characteristics are presented in Table 1. Of
the total sample (n = 193), 60.1% were men. The mean
age was 69.9 ± 9.1 years (range, 35–96).
Self-reported outcomes
Table 2 shows the scores on knowledge, skills, and confi-
dence in self-management (PAM), diabetes self-care be-
havior (SDSCA), health-related quality of life (EQ-5D),
and emotional well-being (WHO-5) of the intervention
and control groups at 0, 6, and 12months. No significant
differences were found between the groups.
Clinical outcomes
The clinical outcomes (HbA1c, BMI, systolic blood pres-
sure, and cholesterol [total, HDL, LDL]) were not reported
in this article due to a large number of missing values.
The missing values varied from 41.8 to 88.8%. Therefore,
it is not possible to make a statement about the clinical ef-
fects. The clinical outcomes are available in an appendix.
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Discussion
We hypothesized that offering the PRISMA program would
result in better self-reported and clinical outcomes in pa-
tients with type 2 diabetes treated in primary care. How-
ever, no effects were found on the following self-reported
outcomes: knowledge, skills and confidence for self-
management, diabetes self-care behavior, health-related
quality of life, and emotional well-being. In addition, it was
not possible to make a statement about the clinical effects.
Previous observational research showed that PRISMA
appeared to improve self-management behavior in terms
of dietary behaviors, foot care, and action planning after 3
months [18]. The lack of effects in self-reported outcomes
in our study may be explained by the already high scores at
baseline. These high scores indicated that the patients in-
cluded in our study had generally well managed type 2 dia-
betes, so there was limited room for improvement. In
addition, Van Vught et al. (2016) observed patients for only
3months. Changes in outcomes could have been dimin-
ished after 6 or 12months. However, PRISMA was ex-
pected to change self-management skills by achieving
personal goals (e.g., losing weight), which usually would be
visible in clinical measures in the intermediate term or lon-
ger. Therefore, in our study, 6 and 12months were logical
terms. Diabetes self-management education interventions
appear most effective when group and individualized inter-
ventions are combined [27]. Therefore, patients probably
need additional encouragement to change their behavior,
such as with follow-up education in either group or indi-
vidual settings.
Some evidence also suggests that contact exceeding 10 h
for diabetes self-management education interventions are
more likely to result in additional decreases in HbA1c [14].
However, PRISMA consisted of two interactive group meet-
ings totaling 7 h [12]. Thus, additional meetings may have
been needed. However, the day-to-day management of type
2 diabetes requires major responsibility from patients. Group
education (combined with access to an online care platform)
would be an extra activity and, as a result, patients could be-
come overwhelmed. Moreover, our target group might not
be interested in this type of interventions, which is the reality
of usual care.
Fig. 1 Flow chart of the randomized controlled trial. RCT = randomized controlled trial
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A strength of this study was that it was embedded in rou-
tine primary diabetes care, which means that it was designed
to test PRISMA in the full spectrum of everyday usual care
to maximize applicability and generalizability. Furthermore,
randomization was performed at a patient level, which gener-
ally decreases influences of health care providers. Some limi-
tations of this study must be mentioned as well. First, the
eight participating general practices diverged in the inclusion
rate: of the 1476 invited patients, most were registered in
three general practices. Thus, the extent to which the health
care providers motivated their patients to participate could
have played a role. However, the characteristics of the pa-
tients (sex, age, education) do reflect the general Dutch
population with type 2 diabetes. Second, in spite of the ex-
pected positive effects, in other studies about 30–50% of the
eligible patients do not participate in diabetes education [28,
29]. In our study this rate was even lower. Despite our efforts
to enthuse patients about the PRISMA program, only 12% of
the approached patients participated. Therefore, selection
bias was very likely. Patients who experience difficulties with
self-management behavior probably do not voluntarily take
part in studies or do not show up at interventions. Moreover,
recruiting from a clinical sample may exclude the patients in
greatest need of self-management, i.e. people who actually do
not visit a general practice. Our target group may have been
uninterested in this type of intervention, which could explain
our low participation rate. If especially motivated patients
participated, this could also explain why the self-reported
and clinical measures were already quite good. However, des-
pite their motivation, 28% of the patients from the interven-
tion group who agreed to participate in the study did not
attend at least one meeting of PRISMA. Patients changed
their mind because were persuaded to enroll by their health-
care provider despite lack of interest. Patients were invited
for PRISMA per letter signed by their own GP. Possibly,
more personal attention in terms of reminding patients by
telephone a couple of days before PRISMA would have pre-
vented dropouts. Third, in an attempt to avoid a type III
error, we monitored as many process factors as possible dur-
ing the implementation of PRISMA. A type III error occurs
when evaluating a program that has not been adequately im-
plemented [30]. Such low intervention fidelity could decrease
the interpretability of the data collected. As mentioned,
PRISMA was guided by different PNs and dieticians, and
their work experience in the diabetes field varied. However,
all trainers used the same protocol and reported deviations
from this protocol after the training. Notable deviations were
not reported. In an ideal situation, the researcher would per-
sonally attend or record all training sessions in order to
check intervention fidelity, however, this was not possibly
due to a lack of time. Fourth, the great number of missing
values in the clinical outcomes should be acknowledged. As
a result, it is not possible to make a statement about the clin-
ical effects. This could be explained by the fact that the study
was carried out in daily practice. The clinical outcomes were
collected annually during the routine diabetes checkups as
part of usual care, and no extra laboratory tests were done.
As a result, we were dependent on the data delivered as part
of usual care. The missing values in the self-reported data
were due to non-responses on the questionnaires. Sending
reminders may have been a solution for this problem but
would have interfered with the restricted time frame in
which questionnaires had to be completed. Fifth, because of
organizational reasons, the patients completed the baseline
questionnaire at the end of the two PRISMA meetings rather
than at the start. We realize this is inconsistent with RCTs,
however, the two PRISMA meetings should be seen as a
starting point to motivate/activate patients, with behavior
change as the final objective. Because we were primarily in-
terested in the outcomes during the months, the influence of
the intervention on completing questionnaires before or after
the intervention was less relevant. Sixth, a sample size calcu-
lation was not specifically performed for examining effects
on the secondary outcomes for the present study [19].
Conclusion
In previous observational research, the diabetes self-
management education program PRISMA seemed to im-
prove self-management behavior after 3months. However,
in this study, PRISMA did not improve self-reported out-
comes (knowledge, skills and confidence for self-
management, diabetes self-care behavior, health-related
quality of life, and emotional well-being) after 6 or 12
months. In addition, it was not possible to make a statement
about the clinical effects given the large number of missing
values. The lack of effects on the outcomes in the current
study does not automatically mean that PRISMA is not ef-
fective in improving self-management skills. Our target
group may have been uninterested in this type of interven-
tion, which is the reality of usual care. Therefore, additional
research is necessary. In pragmatic trials such as the current
study, it is essential to monitor all possible information dur-
ing the implementation phase of the intervention. This will
improve the reliability of the data collected.
Table 1 Baseline patient characteristics (n = 193)






Male 56 (58.9) 60 (61.2)














Type 2 diabetes duration, years 6 (4–8) 6 (4–9)
aLow=no education or primary education; moderate = lower secondary education,
(upper) secondary education or post-secondary non-tertiary education (including
vocational education); high= tertiary education (bachelor’s degree or higher)
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